Jukka Kanerva

2.3k total citations
57 papers, 1.4k citations indexed

About

Jukka Kanerva is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Jukka Kanerva has authored 57 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Public Health, Environmental and Occupational Health, 16 papers in Hematology and 15 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Jukka Kanerva's work include Acute Lymphoblastic Leukemia research (34 papers), Childhood Cancer Survivors' Quality of Life (14 papers) and Acute Myeloid Leukemia Research (10 papers). Jukka Kanerva is often cited by papers focused on Acute Lymphoblastic Leukemia research (34 papers), Childhood Cancer Survivors' Quality of Life (14 papers) and Acute Myeloid Leukemia Research (10 papers). Jukka Kanerva collaborates with scholars based in Finland, Denmark and Sweden. Jukka Kanerva's co-authors include Kjeld Schmiegelow, Ulla M. Saarinen‐Pihkala, Mats Heyman, Kim Vettenranta, Gudmar Lönnerholm, Arja Harila‐Saari, Sakari Knuutila, Tarja Niini, Trond Flægstad and Bendik Lund and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Jukka Kanerva

55 papers receiving 1.4k citations

Peers

Jukka Kanerva
Catherine Cole Australia
Kimikazu Matsumoto Japan
Katsuyoshi Koh Japan
Anja Möricke Germany
Isabel Badell Spain
F Bonetti Italy
Marlène Pasquet France
Luca Lo Nigro Italy
Birgitte Lausen Denmark
Patrick Boutard France
Catherine Cole Australia
Jukka Kanerva
Citations per year, relative to Jukka Kanerva Jukka Kanerva (= 1×) peers Catherine Cole

Countries citing papers authored by Jukka Kanerva

Since Specialization
Citations

This map shows the geographic impact of Jukka Kanerva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jukka Kanerva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jukka Kanerva more than expected).

Fields of papers citing papers by Jukka Kanerva

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jukka Kanerva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jukka Kanerva. The network helps show where Jukka Kanerva may publish in the future.

Co-authorship network of co-authors of Jukka Kanerva

This figure shows the co-authorship network connecting the top 25 collaborators of Jukka Kanerva. A scholar is included among the top collaborators of Jukka Kanerva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jukka Kanerva. Jukka Kanerva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Isohanni, Pirjo, et al.. (2024). Without ENMG, detecting pediatric vincristine neuropathy is a challenge. Clinical Neurophysiology Practice. 9. 94–101.
2.
Murumägi, Astrid, Daniela Ungureanu, Mariliina Arjama, et al.. (2021). STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells. Translational Oncology. 14(4). 101027–101027. 9 indexed citations
3.
Nielsen, Stine Nygaard, Kathrine Grell, Jacob Nersting, et al.. (2021). No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study. Cancer Chemotherapy and Pharmacology. 88(2). 271–279. 6 indexed citations
4.
Rank, Cecilie Utke, Kathrine Grell, Lisbeth Nørgaard Møller, et al.. (2021). Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia. Haematologica. 106(11). 2824–2833. 15 indexed citations
5.
6.
Helle, Emmi, Jaana Pihkala, Timo Jahnukainen, et al.. (2021). Heart Transplantation for Early-Onset Anthracycline-Induced Cardiomyopathy Within 5 Months of Chemotherapy Completion. JACC Case Reports. 3(15). 1677–1679. 1 indexed citations
7.
Nersting, Jacob, Stine Nygaard Nielsen, Kathrine Grell, et al.. (2018). Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy. Cancer Chemotherapy and Pharmacology. 83(1). 53–60. 13 indexed citations
8.
Nielsen, Stine Nygaard, Kathrine Grell, Jacob Nersting, et al.. (2017). DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial. The Lancet Oncology. 18(4). 515–524. 74 indexed citations
9.
Guerrouahen, Bella S., Christos Vaklavas, Jukka Kanerva, et al.. (2010). Dasatinib Inhibits the Growth of Molecularly Heterogeneous Myeloid Leukemias. Clinical Cancer Research. 16(4). 1149–1158. 39 indexed citations
10.
Lund, Bendik, Ann Åsberg, Mats Heyman, et al.. (2010). Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatric Blood & Cancer. 56(4). 551–559. 91 indexed citations
11.
Milani, Lili, Anders Lundmark, Jessica Nordlund, et al.. (2008). Allele-specific gene expression patterns in primary leukemic cells reveal regulation of gene expression by CpG site methylation. Genome Research. 19(1). 1–11. 68 indexed citations
12.
Suominen, Pertti, et al.. (2008). Unrecognized Mediastinal Tumor Causing Sudden Tracheal Obstruction and Out-of-Hospital Cardiac Arrest. Journal of Emergency Medicine. 38(5). e63–e66. 4 indexed citations
13.
Skärby, Tor, H. Anderson, Jesper Heldrup, et al.. (2006). High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia. 20(11). 1955–1962. 90 indexed citations
14.
Palle, Josefine, Britt‐Marie Frost, Erik Forestier, et al.. (2005). Cellular drug sensitivity in MLL-rearranged childhood acute leukemia is correlated to partner genes and cell lineage : On behalf of the Nordic Society for Paediatric Haematology and Oncology. British Journal of Haematology. 129(2). 1 indexed citations
15.
Palle, Josefine, B‐M Frost, Erik Forestier, et al.. (2005). Cellular drug sensitivity in MLL‐rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. British Journal of Haematology. 129(2). 189–198. 24 indexed citations
16.
Frost, Britt‐Marie, Peter Nygren, Göran Gustafsson, et al.. (2003). Increased in vitro cellular drug resistance is related to poor outcome in high‐risk childhood acute lymphoblastic leukaemia. British Journal of Haematology. 122(3). 376–385. 26 indexed citations
17.
Kanerva, Jukka, Ulla M. Saarinen‐Pihkala, Tarja Niini, et al.. (2003). Favorable outcome in 20‐year follow‐up of children with very‐low‐risk ALL and minimal standard therapy, with special reference to TEL–AML1 fusion. Pediatric Blood & Cancer. 42(1). 30–35. 8 indexed citations
18.
Kanerva, Jukka, Kim Vettenranta, K. Autio, Sakari Knuutila, & Ulla M. Saarinen‐Pihkala. (2002). Minimal residual disease by metaphase FISH in children with ALL: clonal cells during or after chemotherapy may not predict relapse. Leukemia Research. 26(6). 545–550. 1 indexed citations
19.
Kanerva, Jukka, Maarit Tiirikainen, Anne Mäkipernaa, et al.. (2001). INITIAL P-GLYCOPROTEIN EXPRESSION IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: NO EVIDENCE OF PROGNOSTIC IMPACT IN FOLLOW-UP. Pediatric Hematology and Oncology. 18(1). 27–36. 21 indexed citations
20.
Kanerva, Jukka, et al.. (1999). Comparative Genomic Hybridization and Conventional Cytogenetic Analyses in Childhood Acute Myeloid Leukemia. Leukemia & lymphoma. 35(3-4). 311–315. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine Cole Breakdown of academic impact, for papers by Kimikazu Matsumoto Breakdown of academic impact, for papers by Katsuyoshi Koh Breakdown of academic impact, for papers by Anja Möricke Breakdown of academic impact, for papers by Isabel Badell Breakdown of academic impact, for papers by F Bonetti Breakdown of academic impact, for papers by Marlène Pasquet Breakdown of academic impact, for papers by Luca Lo Nigro Breakdown of academic impact, for papers by Birgitte Lausen Breakdown of academic impact, for papers by Patrick Boutard
Rankless by CCL
2026